Gilead Sciences (NASDAQ:GILD) Price Target Raised to $165.00 at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) had its price objective hoisted by investment analysts at Wells Fargo & Company from $150.00 to $165.00 in a research note issued on Wednesday,MarketScreener reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 7.47% from the stock’s current price.

Several other brokerages have also commented on GILD. Needham & Company LLC upped their target price on Gilead Sciences from $140.00 to $170.00 and gave the company a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday. Sanford C. Bernstein set a $135.00 price objective on Gilead Sciences and gave the company an “outperform” rating in a research note on Monday, December 29th. Finally, Rothschild & Co Redburn boosted their price target on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Twenty-five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.85.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $153.54 on Wednesday. The company has a market cap of $190.49 billion, a P/E ratio of 23.65, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences has a one year low of $93.37 and a one year high of $153.13. The firm’s fifty day moving average price is $128.39 and its two-hundred day moving average price is $121.53.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This represents a 16.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 319,391 shares of company stock worth $44,141,101 over the last quarter. 0.27% of the stock is owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Norges Bank purchased a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $2,617,152,000. Ameriprise Financial Inc. boosted its holdings in Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after buying an additional 4,113,999 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Needham reiterated a Buy and raised its price target to $170, reflecting confidence in HIV momentum and margin expansion. Analyst Note
• Positive Sentiment: Scotiabank raised its price target from $140 to $177 and kept a “sector outperform” stance — a sizable upside vs. the current price that supports further upside expectations. Benzinga
• Positive Sentiment: Cantor Fitzgerald bumped its target to $155 and moved to Overweight, adding institutional buying interest. Benzinga
• Positive Sentiment: Gilead beat Q4 estimates — $1.86 EPS vs. $1.83 consensus and revenue roughly $7.9B — signaling continued strength in its core HIV and liver-disease franchises. Reuters
• Positive Sentiment: Board approved a 3.8% quarterly dividend increase to $0.82 per share (payable March 30), supporting income investors and the yield profile. Business Wire
• Neutral Sentiment: Q4 earnings materials and the conference call transcript provide detail on product trends (Yeztugo launch, HIV portfolio). Useful for modeling revenue cadence but not immediate market-moving by itself. Yahoo Finance
• Negative Sentiment: Gilead’s FY‑2026 guidance came in light: EPS guidance $8.45–$8.85 (consensus ~$8.69) and revenue guidance $29.6–$30.0B vs. ~$30.1B consensus — investors focused on the downside of the outlook. Benzinga
• Negative Sentiment: Because guidance missed some street expectations, shares dipped in after‑hours/extended trading — the immediate market reaction is driven more by forward guidance than yesterday’s beat. MSN

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.